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Abstract
Health economic evaluations face the issues of non-compliance and
missing data. Here, non-compliance is defined as non-adherence to
a specific treatment, and occurs within randomised controlled tri-
als (RCTs) when participants depart from their random assignment.
Missing data arises if, for example, there is loss to follow-up, survey
non-response, or the information available from routine data sources is
incomplete. Appropriate statistical methods for handling non-compliance
and missing data have been developed, but they have rarely been ap-
plied in health economics studies. Here, we illustrate the issues and
outline some of the appropriate methods to handle these with an ap-
plication to a health economic evaluation that uses data from an RCT.
In an RCT the random assignment can be used as an instrument
for treatment receipt, to obtain consistent estimates of the complier
average causal effect, provided the underlying assumptions are met.
Instrumental variable methods can accommodate essential features of
the health economic context such as the correlation between individ-
uals’ costs and outcomes in cost-effectiveness studies. Methodological
guidance for handling missing data encourages approaches such as
multiple imputation or inverse probability weighting, that assume the
data are Missing At Random, but also sensitivity analyses that recog-
nise the data may be missing according to the true, unobserved values,
that is, Missing Not at Random.
Future studies should subject the assumptions behind methods
for handling non-compliance and missing data to thorough sensitivity
analyses. Modern machine learning methods can help reduce reliance
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on correct model specification. Further research is required to develop
flexible methods for handling more complex forms of non-compliance
and missing data.
Key words: non-compliance; missing data; instrumental variables; multi-
ple imputation; inverse probability weighting; sensitivity analyses
1 Introduction
Health economic studies that evaluate technologies, health policies or pub-
lic health interventions are required to provide unbiased, efficient estimates
of the causal effects of interest. Health economic evaluations are recom-
mended to use data from well-designed randomised controlled trials (RCTs).
However, a common problem in RCTs is non-compliance, in that trial partic-
ipants may depart from their randomised treatment. Brilleman et al. (2015)
highlight that when faced with non-compliance, health economic evaluations
have resorted to ‘per protocol’ (PP) analyses. A PP analysis excludes those
patients who depart from their randomised allocation, and as the decision to
switch treatment is likely to be influenced by prognosis, is liable to provide
biased estimates of the causal effect of treatment receipt (Ye et al, 2014).
Another concern is that the required data on outcomes, resource use or
covariates may be missing for a substantial proportion of patients. Miss-
ing data can arise when patients are lost to follow-up, fail to complete the
requisite questionnaires, or when information from routine data sources is in-
complete. Most published health economic studies use methods that assume
the data are Missing Completely at Random (Noble et al, 2012; Leurent et
al, 2017). A related concept is ‘censoring’ which refers specifically to when
some patients are follow-up for less than the full period of follow-up. For
example, in an RCT, those participants who are recruited later to the study,
may have their survival data censored at the end of the study period, and
it may be reasonable to assume that these data are ‘censored completely at
random’ also known as non-informative censoring (Willan and Briggs, 2006).
More generally in health economic studies, neither non-compliance, nor
missing data are likely to be completely at random, and could be associated
with the outcome of interest. Unless the underlying mechanisms for the
non-compliance or missing data are recognised in the analytical methods,
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health economic studies may provide biased, inefficient estimates of the causal
effects of interest. Appropriate methods for handling non-compliance and
missing data have been developed in the wider biostatistics and econometrics
literatures (see for example Angrist et al (1996); Robins (1994); Bang and
Robins (2005); Little and Rubin (2002); Molenberghs and Kenward (2007);
Heckman (1979)), but reviews report low uptake of these methods in applied
health economics studies (Noble et al, 2012; Latimer et al, 2014; Brilleman
et al., 2015; Leurent et al, 2017).
Several authors have proposed approaches for handling non-compliance
and missing data, suitable for the applied health economics context. In par-
ticular, DiazOrdaz et al (2017), propose methods for handling non-compliance
in cost-effectiveness studies that use RCTs, Latimer et al (2014) and White
(2015) exemplify methods for handling non-compliance with survival (time
to event) outcomes, while Blough et al (2009); Briggs et al (2003); Burton
et al (2007); DiazOrdaz et al (2014, 2016); Faria et al (2014) and Gomes et
al (2013) exemplify methods for handling missing data in health economic
evaluations.
The objective of this chapter is to describe and critique alternative meth-
ods for handling non-compliance and missing data in health economics stud-
ies. The methods are illustrated with a health economic evaluation that
uses data from a single RCT, but we also consider these methods in health
economic studies more widely, and identify future research priorities. The
chapter proceeds as follows. First, we exemplify the problems of both non-
compliance and missing data with the REFLUX case study. Second, we
define the necessary assumptions for identifying the parameters of interest,
and propose estimation strategies for addressing non-compliance, and then
missing data. Third, we contrast some alternative methods in the context
of trial-based health economic evaluation. Fourth, we briefly review devel-
opments from the wider methodological literature, and identify key research
priorities for future health economics studies.
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2 Motivating example: Cost-effectiveness anal-
ysis using the REFLUX study
The REFLUX study was a UK multicentre RCT with a parallel design,
in which patients with moderately severe gastro-oesophageal reflux disease
(GORD), were randomly assigned to medical management or laparoscopic
surgery (Grant et al, 2008, 2013). Resource use and health-related quality
of life (QoL), assessed by the EQ-5D (3 levels), were recorded annually for
up to five years. Table 1 reports the main characteristics of the study. The
original cost-effectiveness analysis (CEA) estimated the linear additive treat-
ment effect on mean costs, Y1i and QALYs, Y2i with a seemingly unrelated
regression (SUR) model (Zellner, 1962; Willan et al., 2004). This model al-
lows for correlation between individual QALYs and costs, and can adjust for
different baseline covariates in each of the equations.
For example, below we have a system of equations that adjust both out-
comes for the EQ-5D utility score at baseline, denoted by EQ5D0:
Y1i = β0,1 + β1,1treati + β1,2EQ5D0i + 1i
Y2i = β0,2 + β1,2treati + β2,2EQ5D0i + 2i
(1)
here β1,1 and β1,2 represent the incremental costs and QALYs respectively.
The error terms are required to satisfy E[1i] = E[2i] = 0, E[`i`′i] =
σ``′ , E[`i`′j] = 0, for `, `
′ ∈ {1, 2}, and for i 6= j.
This is an example of a special type of SUR model, in which the same set
of covariates is used in all the equations, the so-called multivariate regression
model.
Since each equation in the SUR system is a regression, consistent esti-
mation could be achieved by OLS, but would be inefficient. The efficient
estimation is generalised least squares (GLS), which requires that the co-
variance matrix is known 1, or the feasible version (FGLS), which uses a
consistent estimate of the covariance matrix when estimating the coefficients
in equation (1) (Zellner, 1962; Zellner and Huang, 1962).
There are some situations where GLS (and FGLS) will not be any more
efficient than OLS estimation: (1) if the regressors in a block of equations in
1If we are prepared to assume the errors are bivariate normal, estimation can proceed
by maximum likelihood.
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the system are a subset of those in another block of the same system, then
GLS and OLS are identical when estimating the parameters of the smaller
set of equations, and (2) in the special case of multivariate regression, where
the SUR equations have identical explanatory variables, OLS estimation is
identical to GLS (Davidson and MacKinnon, 2004).
The SUR approach can be used to estimate incremental cost and health
effects, which in turn can be used to produced incremental cost-effectiveness
ratios (ICERs) and incremental net monetary benefits (INBs). Here we focus
on the INB, defined as INB(λ) = λβ1,2 − β1,1, where λ is the willingness
to pay threshold. The standard error of the INB can be calculated from
the standard errors and correlations of the estimated incremental costs and
QALYs βˆ1,1 and βˆ1,2, following usual rules for estimating the variance of a
linear combination of two random variables.
In the REFLUX trial a sizeable minority of the patients crossed over from
their randomised treatment assignment (see Table 1), and the proportions
of patients who switched in the RCT were higher than in routine clinical
practice (Grant et al, 2008, 2013). In the RCT, cost and QoL data were
missing for a high proportion of the patients randomly assigned to either
strategy.
The original study reported a PP analysis (Grant et al, 2013), but this
is liable to provide a biased estimate of the causal effect of the treatment
received. Faced with missing data, the REFLUX study used multiple impu-
tation (MI) and complete case analysis (CCA). In Section 6, we re-analyse
the REFLUX study with the methods described in the next sections to re-
port a causal effect of the receipt of surgery versus medical management that
uses all the available data, and recognises the joint distribution of costs and
QALYs.
Next, we consider approaches taken to the issue of non-compliance in
health economic evaluation more widely, and provide a framework for esti-
mating causal effects in CEA.
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Table 1: The REFLUX study: descriptive statistics and levels of missing
data over the five year follow-up period
 
	
 Medical management Laparoscopic surgery 
N Assigned 179 178 
N (%) missing baseline EQ-5D 6(3) 7(4) 
 Mean (SD) observed baseline EQ-5D  0.72(0.25) 0.71(0.26) 
N (%) switched 10(8.3) 67(28.4) 
N (%) missing costs 83(46)   83(47) 
 Mean (SD) observed cost [£ GBP] 1,316(1728) 2,978(1826) 
N (%) missing QALYs 91(51) 94(53) 
 Mean (SD) observed QALYs  3.52(0.99) 3.74(0.90) 
Correlation between individual costs and 
QALYs, according to treatment assigned   
-0.43 -0.04 
Correlation between individual costs and 
QALYs, according to treatment received 
-0.36 -0.18 
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3 Non-compliance in health economic evalu-
ation
The intention-to-treat (ITT) estimand can provide an unbiased estimate of
the intention to receive a particular treatment, but not of the causal ef-
fect of the treatment actually received. Instrumental variable (IV) methods
can identify the complier average causal effect (CACE), also known as the
local average treatment effect (LATE). In RCTs with non-compliance, ran-
dom assignment can act as the instrument for treatment receipt, provided it
meets the IV criteria for identification (Angrist et al, 1996). An established
approach to IV estimation is two-stage least squares (2sls), which provides
consistent estimates of the CACE when the outcome model is linear, and
non-compliance is binary (Baiocchi et al, 2014).
In CEA that use RCT data, there is interest in estimands, such as the
relative cost-effectiveness for compliers. An estimate of the causal effect of
the treatment received can help with the interpretation of results from RCTs
with different levels of non-compliance to those in the target population. The
causal effect of treatment receipt is also of interest in RCTs with encourage-
ment designs, for example of behavioural interventions to encourage uptake
of new vaccines (Duflo et al, 2008), and for trial designs, common in oncology,
which allow treatment switching according to a variable time period, such as
after disease progression (Latimer et al, 2014) (see Section 7.3.2).
In CEA, methods that report the causal effect of the treatment have
received little attention. Brilleman et al. (2015) found that most studies
that acknowledged the problem of non-compliance reported PP analyses,
while Hughes et al (2016) suggested that further methodological development
was required. The context of trial-based CEA raises important complexities
for estimating CACEs that arise more generally in studies with multivariate
outcomes. Here to provide accurate measures of the uncertainty surrounding
a composite measure of interest, for example the INB, it is necessary to
recognise the correlation between the endpoints, in this case, cost and health
outcomes (Willan et al, 2003; Willan, 2006).
We now provide a framework for identifying and estimating the causal
effects of the treatment received. First, we present the three stage least
squares (3sls) method (Zellner and Theil, 1962), which allows the estimation
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of a system of simultaneous equations with endogenous regressors. Next,
we consider a bivariate Bayesian approach, whereby the outcome variables
and the treatment received are jointly modelled as dependent on random
assignment. This extends IV unrestricted reduced form (Kleibergen and
Zivot, 2003), to the setting with multivariate outcomes.
4 Complier Average Causal effects with bi-
variate outcomes
We begin by defining more formally our estimand and assumptions. Let Y1i
and Y2i be the continuous bivariate outcomes, and Zi and Di the binary ran-
dom treatment allocation and treatment received respectively, corresponding
to the i-th individual. The bivariate endpoints Y1i and Y2i belong to the same
individual i, and thus are correlated. We assume that there is an unobserved
confounder U , which is associated with the treatment received and either or
both of the outcomes. We assume that the (i) Stable Unit Treatment
Value Assumption (SUTVA) holds: the potential outcomes of the i-th in-
dividual are unrelated to the treatment status of all other individuals (known
as no interference), and that for those who actually received treatment level
z, their observed outcome is the potential outcome corresponding to that
level of treatment.
Under SUTVA, we can write the potential treatment received by the i-th
subject under the random assignment at level zi ∈ {0, 1} as Di (zi). Similarly,
Y`i (zi, di) with ` ∈ {1, 2} denotes the corresponding potential outcome for
endpoint `, if the i-th subject were allocated to level zi of the treatment and
received level di. There are four potential outcomes. Since each subject is
randomised to one level of treatment, only one of the potential outcomes per
endpoint `, is observed, i.e. Y`i = Y`i(zi, Di(zi)) = Yi(zi).
The CACE for outcome ` can now be defined as
θ` = E
[{Y`i(1)− Y`i(0)}∣∣{Di(1)−Di(0) = 1}] . (2)
In addition to SUTVA, the following assumptions are sufficient for iden-
tification of the CACE, (Angrist et al, 1996):
(ii) Ignorability of the treatment assignment: Zi is independent of
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unmeasured confounders (conditional on measured covariates) and the po-
tential outcomes Zi ⊥⊥ Ui, Di(0), Di(1), Yi(0), Yi(1).
(iii) The random assignment predicts treatment received: Pr{Di(1) =
1} 6= Pr{Di(0) = 1}.
(iv) Exclusion restriction: The effect of Z on Y` must be via an effect of
Z on D; Z cannot affect Y` directly.
(v) Monotonicity: Di(1) ≥ Di(0).
The CACE can now be identified from equation (2) without any further
assumptions about the unobserved confounder; in fact, U can be an effect
modifier of the relationship between D and Y (Didelez et al, 2010).
In the REFLUX study, the assumptions concerning the random assign-
ment, (ii) and (iii), are justified by design. The exclusion restriction assump-
tion is plausible for the cost endpoint, as the costs of surgery are only incurred
if the patient actually has the procedure, and it seems unlikely that assign-
ment rather than receipt of surgery would have a direct effect on QALYs.
The monotonicity assumption rules out the presence of defiers, and it seems
reasonable to assume that there are no trial participants who would only
receive surgery if they were randomised to medical management, and vice
versa. Equation (2) implicitly assumes that receiving the intervention has
the same average effect on the linear scale, regardless of the level of Z and
U .
Since random allocation, Z, satisfies assumptions (ii)-(iv), we say it is an
instrument for D. For a binary instrument, the simplest approach to estimate
equation (2) within the IV framework is the Wald estimand (Angrist et al,
1996):
β` =
E(Y |Z = 1)− E(Y |Z = 0)
E(D|Z = 1)− E(D|Z = 0)
Typically, estimation of these conditional expectations proceeds via the so-
called two-stage least squares (2sls). The first stage is a linear regression
model that estimates the effect of the instrument on the exposure of interest,
here treatment received on treatment assigned. The second stage is the
outcome regression model, but fitted on the predicted treatment received
from the stage one regression:
Di = α0 + α1Zi + 0,i
Y`i = β0 + β1,`D̂i + `,i (3)
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where β̂1,` is an estimator for β`. Covariates can be included in both model
stages.
For 2sls to be consistent, the first stage model must be the paramet-
ric linear regression implied by the second stage, that is, it must include
all the covariates and interactions that appear in the second stage model
(Wooldridge, 2010).
The asymptotic standard error for the 2sls estimate of the CACE is given
in Imbens and Angrist (1994), and is available in commonly used software
packages. However, 2sls can only be readily applied to univariate outcomes,
which raises an issue for CEA as ignoring the correlation between the two
endpoints would provide inaccurate measures of uncertainty. A simple way
to address this problem would be to apply 2sls directly within a net bene-
fit regression approach (Hoch et al, 2006). However, it is known that net
benefit regression is very sensitive to outliers, and to distributional assump-
tions (Willan et al., 2004), (Mantopoulos et al, 2016). Instead, we focus
on strategies for jointly estimating the CACE on QALYs and costs. The
first approach combines SURs (equation 1) with 2sls (equation 3) to obtain
CACEs for both outcomes accounting for their correlation, and is known as
three-stage least squares (3sls). The second is a Bayesian estimation method
for the system of simultaneous equations.
4.1 Three-stage least squares
Three-stage least squares (3sls) was developed as a generalisation of 2sls for
systems of equations with endogenous regressors, i.e. any explanatory vari-
ables which are correlated with the error term in its corresponding equation
(Zellner and Theil, 1962).
Di = α0 + α1Zi + e0i
Y1i = β01 + βIV,1Di + e1i (4)
Y2i = β02 + βIV,2Di + e2i (5)
As with 2sls, the models can be extended to include baseline covariates.
All the parameters appearing in the system of equations (4) and (5) are
estimated jointly. Firstly, the IV model is estimated “outcome by outcome”,
for example by applying 2sls. This will be consistent but inefficient. The
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residuals from this 2sls models, that is e1i and e2i, can be now used to esti-
mate the covariance matrix that relates the outcome models. This is similar
to the step used on a SUR with exogenous regressors (equation (1)) for es-
timating the covariance matrix of the error terms from the two equations
(4) and (5). This estimated covariance matrix is used when solving the esti-
mating equations formed by stacking the equations vertically (Davidson and
MacKinnon, 2004).
Provided that the identification assumptions (i)-(v) are satisfied, Z is
independent of the residuals at each stage, i.e. Z ⊥⊥ e0i, Z ⊥⊥ e1i, and
Z ⊥⊥ e2i, the estimating equations can be solved by FGLS which avoids
distributional assumptions, and is also robust to heteroscedasticity of the
errors across the different linear models for the outcomes (Greene, 2002). As
the 3sls method uses an estimated covariance matrix, it is only asymptotically
efficient (Greene, 2002). If the error terms in each equation of the system and
the instrument are not independent, the 3sls estimator based on FGLS is not
consistent, and other estimation approaches, such as generalised methods of
moments (GMM) warrant consideration (Schmidt, 1990).
In the just-identified case, that is when there are as many endogenous
regressors as there are instruments, classical theory shows that the GMM
and the FGLS estimators coincide (Greene, 2002).
4.2 Bayesian estimators
Nixon and Thompson (2005) propose Bayesian bivariate models for the ex-
pectations of the two outcomes (e.g. costs and QALYs) in CEA, which
have a natural appeal for this context as each endpoint can be specified as
having a different distribution. The parameters in the models are simulta-
neously estimated, allowing for proper Bayesian feedback and propagation
of uncertainty. On the other hand, univariate instrumental variables models
within the Bayesian framework have been previously developed (Burgess and
Thompson, 2012; Kleibergen and Zivot, 2003; Lancaster, 2004).
This method recasts the first and second stage equations familiar from
2sls, eqs. (3), in terms of a recursive equation model, which can be “solved”
by substituting the parameters of the first into the second. Such solved
system of equations is called the reduced form, and it expresses explicitly
how the endogenous variable D and the outcome Y` jointly depend on the
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instrument.
D = α0 + α1Z + ν0
Y` = β
∗
0 + β1,`α1Z + ν` (6)
where β∗0 = β0 + β1,`α0, ν0 = 0 and ν` = ` + β0.
The parameter of interest β1,` is identified, since by the IV assumptions,
α1 6= 0.
The extension of this reduced form to multivariate outcomes proceeds as
follows. Let (Di, Y1i, Y2i)
> be the transpose of the vector of outcomes, which
now includes the endogeneous variable D as well as the bivariate endpoints
of interest.
The reduced form can now be written in terms of the linear predictors of
Di, Y1i, Y2i as :
µ0i = β0,0 + β1,0Zi
µ1i = β0,1 + β1,1β1,0Zi
µ2i = β0,2 + β1,2β1,0Zi
(7)
with β0,0 = α0, β1,0 = α1.
We treat Di, Y1i, Y2i as multivariate normally distributed, so that:DiY1i
Y2i
 ∼ N

 µ0iµ1i
µ2i
 ,Σ =
σ20 s01 s02s01 σ21 s12
s02 s12 σ
2
2

 ; (8)
where sij = cov(Yi, Yj), and the causal treatment effect estimates are β1,1 and
β1,2 respectively. For the implementation, we use vague normal priors for the
regression coefficients, i.e. βm,j ∼ N(0, 102), for j ∈ {0, 1, 2},m ∈ {0, 1}, and
a Wishart prior for the inverse of Σ (Gelman and Hill, 2006).
4.3 Comparison of Bayesian versus 3sls estimators for
CEA with non-compliance
The performance of 3sls and Bayesian methods for obtaining compliance-
adjusted estimates was found to be similar in a simulation study (DiazOrdaz
et al, 2017). Under the IV and monotonicity assumptions, both approaches
performed well in terms of bias and confidence interval coverage, though the
Bayesian estimator reported wide CIs around the estimated INB in small
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sample size settings. The 3sls estimator reported low levels of bias and good
CI coverage throughout.
These estimators rely on a valid IV and for observational data settings,
the assumptions required for identification warrant particular scrutiny. While
the use of IV estimators in health economics studies has not been extensive,
the development of new large, linked observational datasets offer new op-
portunities for harnessing IVs to estimate the causal effects of treatments
received. In particular, areas such as Mendelian randomisation offer the pos-
sibility of providing valid instruments and have previously been used with
the Bayesian estimators described above (Burgess and Thompson, 2012).
Methods are also available which do not rely on an IV, but still attempt
to estimate a causal effect of treatment receipt. We briefly review one of
these methods below.
4.4 Inverse probability weighting for non-compliance
Inverse probability weighting (IPW) can also be used to obtained compliance-
adjusted estimates. Under IPW, observations that deviate from protocol are
censored, similar to a PP analysis. To avoid selection bias, the data from
those participants that continue with the treatment protocol are weighted, to
represent the complete (uncensored) sample according to observed character-
istics. The weights are given by the inverse of the probability of complying,
conditional on the covariates included in the non-compliance model.
The target estimand is the causal average treatment effect (ATE). For
IPW to provide unbiased estimates of the ATE, requires that the model in-
cludes all baseline and time-dependent variables that predict both treatment
non-adherence and outcomes. This is often referred to as the “no unobserved
confounder” assumption (Robins and Finkelstein, 2000). Latimer et al (2014)
illustrate IPW for health technology assessment.
The IPW method cannot be used when there are covariates values that
perfectly predict treatment non-adherence, that is when there are covariate
levels where the probability of non-adherence is equal to one (Robins, 2000;
Herna´n et al, 2001; Yamaguchi and Ohashi, 2004). We consider further meth-
ods for handling non-compliance in health economic studies in Section 7. We
turn now to the problem of missing data.
13
5 Missing data
The approach to handling missing data should be in keeping with the general
aim of providing consistent estimates of the causal effect of the interventions
of interest. However, most published health economic evaluations simply
discard the observations with missing data, and undertake complete case
analyses (CCA) (Noble et al, 2012; Leurent et al, 2017). This approach is
valid, even if inefficient, where the probability of missingness is indepen-
dent of the outcome of interest given the covariates in the analysis model,
that is there is covariate-dependent missingness (CDM) (White and Carlin,
2010). A CCA is also valid when the data are missing completely at random
(MCAR) (Little and Rubin, 2002), that is the missing data do not depend
on any observed, or unobserved value. Similarly, when data are censored for
administrative reasons unrelated to the outcome, then they may be assumed
to be censored completely at random (Willan and Briggs, 2006).
In many health economic evaluations it is more realistic to assume that
the data are missing (or censored) at random (MAR), that is, that the prob-
ability that the data are observed, only depends on observed data (Little and
Rubin, 2002). For example, a likelihood-based approach that only uses the
observed data, can still provide valid inferences under the MAR assumption,
if the analysis adjusts for all those variables associated with the probability
of missing data (Molenberghs and Kenward, 2007)
For SUR systems, it can often be the case that each equation has dif-
ferent number of observations, either because of differential missingness in
the outcomes or because each equation included different regressors, which
in turn have alternative missing data mechanisms. Estimation methods for
SUR models with unequal numbers of observations have been considered by
Schmidt (1977). Such estimates would then be valid under the asumptions
of CDM or MCAR. In addition, if the estimation method was likelihood-
based (MLE, Expectation-Maximisation and Bayesian), the estimates are
also valid under MAR, again provided the models adjust for all the variables
driving the missingness. Estimation of SUR systems with unequal number
of observations based on Maximum-likelihood was presented by Foschi and
Kontoghiorghes (2002) within the frequentist literature. Bayesian likelihood
estimation of SURs with unequal number of observations was developed by
Swamy and Mehta (1975).
14
In general, MI, IPW and full Bayesian methods are the recommended
approaches if the data can be assumed to be MAR (Rubin, 1987). Meth-
ods that assume data are MAR have been proposed in health economics, for
example to handle missing resource use and outcomes (Briggs et al, 2003)
or unit costs (Grieve et al, 2010). In the specific context of censored data,
time to event parametric models have been adapted to the health economics
context, and assume that the censoring is un-informative, that is the proba-
bility that the data are censored only depends on the observed data, see for
example Lin et al. (1997); Carides et al. (2000); Raikou and McGuire (2004,
2006), and also section 7.3.3.
An alternative assumption is that the missing values are associated with
data that are not observed, that is the data are missing not at random
(MNAR). Methods guidance for the analysis of missing data recommends
that, while the primary or base case analysis should present results assuming
MAR, sensitivity analyses should be undertaken that allow for the data to
be MNAR (Sterne et al, 2009). The review by Leurent et al (2017) highlights
that there are very few examples in health economics studies that consider
MNAR mechanisms (see section 7.2).
5.1 Multiple Imputation (MI)
MI is a principled tool for handling missing data (Rubin, 1987). MI requires
the analyst to distinguish between two statistical models. The first model
called the substantive model, model of interest or analysis model is the one
that would have been used had the data been complete. The second model,
called the imputation model, is used to describe the conditional distribution of
the missing data, given the observed, and must include the outcome. Missing
data are imputed with the imputation model, to produce several completed
data sets. Each set is then analysed separately using the original analysis
model, with the resultant parameter estimates and associated measures of
precision combined by Rubin’s formulae (Rubin, 1987), to produce the MI
estimators and their variances. Under the MAR assumption, this will pro-
duce consistent estimators (Little and Rubin, 2002; Schafer, 1997). MI can
increase precision, by incorporating partly observed data, and remove po-
tential bias from undertaking a CCA when data are MAR. If only outcomes
are missing, MI may not improve upon a conventional likelihood analysis
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(White and Carlin, 2010). Nevertheless, MI can offer improvements if the
imputation model includes variables that predict missingness and outcome,
additional to those in the analysis model. The inclusion of these so-called
auxiliary variables can make the assumption that the data are MAR more
plausible.
A popular approach to MI is full-conditional specification (FCS) or chained
equations MI, where draws from the joint distribution are approximated us-
ing a sampler consisting of a set of univariate models for each incomplete
variable, conditional on all the other variables (van Buuren , 2012). FCS has
been adapted to include interactions and other non-linear terms in the im-
putation model, so that the imputation model contains the analysis model.
This approach is known as substantive model compatible FCS (SMCFCS)
(Bartlett et al, 2014).
Faria et al (2014) present a guide to handling missing data in CEA con-
ducted within trials, and show how MI can be implemented in this context.
5.2 IPW for valid inferences with missing data
IPW can address missing data, by using weights to re-balance complete cases
so that they represent the original sample. The use of IPW for missingness
is similar to re-weighting different sampling fractions within a survey. The
units with a low probability of being fully observed, are given a relatively
high weight so that they represent units with similar (baseline) characteristics
who were not fully observed, and would be excluded from a CCA.
The weighting model p(Ri = 1|Xi, Yi) is called the probability of miss-
ingness model (POM). From this model, we can estimate the probability of
being observed, by for example, fitting a logistic model and obtaining fit-
ted probabilities pii. The weights wi, are then the inverse of these estimated
probabilities, i.e. wi =
1
pii
.
The IPW approach incorporates this re-weighting in applying the sub-
stantive model to the complete cases. IPW provides consistent estimators
when the data are MAR and the POM models are correctly specified. The
variance of the IPW estimator is consistently estimated provided the weight-
ing is taken into account, by for example using a sandwich estimator (Robins
et al, 1994). IPW is simple to implement when there is only one variable
with missing data, and the POM model only includes predictors that are
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fully-observed. It is still fairly straight-forward, when there are missing data
for more variables but the missing data pattern or missingness is monotone,
which is the case when patients drop out of the study follow-up after a partic-
ular timepoint. The tutorial by Seaman and White (2011) provides further
detail on using IPW for handling missing data.
IPW has rarely been used to address missing data in health economic
evaluation (Leurent et al, 2017; Noble et al, 2012). Here a particular concern
is that there may be poor overlap between those observations with fully-
versus partially- observed data according to the variables that are in the
POM model, leading to unstable weights. There are precedents for using
IPW in health economics settings with larger datasets, and where lack of
overlap is less of a problem (see Jones et al (2006)). IPW and MI both
provide consistent estimates under MAR, if either the POM or imputation
models are correctly specified. However, MI is often preferred to IPW, as it is
usually more efficient and more flexible approach for handling non-monotone
patterns of missing data, for example when data are missing at intermittent
time-points during the study follow-up.
5.3 Bayesian analyses
Bayesian analyses naturally distinguish between observed data and unob-
served quantities. All unobserved quantities are viewed as unknown “param-
eters” with an associated probability distribution. From this perspective,
missing values simply become extra parameters to model and obtain poste-
rior distributions for. Let θ denote the parameters of the full data model,
p(y, r|x; θ). This model can be factorised as the substantive model times the
POM, i.e. the model for the missingness mechanism p(y|x; γ)p(r|y, x;ψ).
For Bayesian ignorability to hold, we need to assume MAR, and in addi-
tion that γ and ψ are a distinct set of parameters, i.e. variation independent,
with the prior distribution for θ factorising into p(θ) = p(γ)p(ψ).
This means that under Bayesian ignorability, if there are covariates in the
analysis model which have missing data, additional models for the distribu-
tion of these covariates are required. These models often involved parametric
assumptions about the full data. The Bayesian approach also uses priors to
account for uncertainty about the POM. This is in contrast to IPW, for ex-
ample, which ignores the uncertainty in the parametric POM, and relies on
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this model being correctly specified. It is possible to use auxiliary variables
under Bayesian ignorability. Full details are provided by Daniels and Hogan
(2008).
6 Application to estimating the CACE with
non-response in the REFLUX study
We now apply 3sls and Bayesian IV models to obtain CACE of the surgery vs
medical management treatment, using the REFLUX example. We compare
CCA with MI, IPW and full Bayesian approaches assuming the missing data
under MAR. Only 48% of trial participants had completely observed costs
and QoL data, with a further 13 missing baseline EQ5D0.
For the CCA, SUR is applied to the cases with full information to re-
port the INB according to the ITT and PP estimands. As Table 2 shows,
the PP estimate is somewhat lower than the ITT and CACE estimates, re-
flecting that those patients who switch from surgery to medical management
and are excluded from this analysis, have a somewhat better prognosis than
those who follow their assigned treatment. Assuming that randomisation
is a valid IV and that monotonicity holds, either 2sls or Bayesian methods
provide CACE estimates of the INB for compliers. However, these CCA
assume that the missingness is independent of the outcomes, given the treat-
ment received and the baseline EQ5D, that is there is covariate-dependent
missingness (CDM). This assumption may be implausible. We now consider
strategies valid under a MAR assumption, specifically, we use MI and IPW
coupled with 3sls, and a full Bayesian analysis, to obtain valid inferences for
the CACE, that use all the available data.
For the MI, we considered including auxiliary variables in the imputa-
tion model, but none of the additional covariates were associated with the
missingness and the value of the variables to be imputed. We imputed total
cost, QALYs and baseline EQ5D0, 50 times by FCS, with predictive mean
matching (PMM), taking the five nearest neighbours as donors (White et al,
2011). The imputation models must contain, all the variables in the analyses
models, and so we included treatment receipt in the imputation model, and
stratified by randomised arm. We then applied 3sls to each of the 50 MI sets,
and combined the results with Rubin’s formulae (Rubin, 1987).
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The IPW required POM models for the baseline EQ5D, cost, and QALY
respectively. Let R0i, R1i and R2i be the respective missingness indicators.
The missingness pattern is almost monotone, with 156 individuals with ob-
served EQ5D0, i.e. R0i = 1, then a further 16 with R0i = R1i = 1, and 10
with all Rji = 0.
2
With this monotone missing pattern we have POMs for: R0i on all other
fully observed baseline covariates; R1i on fully observed baseline covariates,
randomised arm treatment receipt, R0 and EQ5D0; and R2i on fully observed
baseline covariates, randomised arm, treatment receipt, R0, EQ5D0, R1, and
cost. We fitted these models with logistic regression, used backward stepwise
selection, and only kept those regressors with p-values less than 0.1. This
resulted in POMs as follows: an empty model for R0i; age, randomised group,
treatment received, and EQ5D0, for the R1i, and only EQ5D0 for R2i. We
obtained the predicted probabilities of being observed, and weighted the
complete cases in the 3sls analysis by the inverse of the product of these
three probabilities.
In the Bayesian analyses, to provide a posterior distribution for the miss-
ing values, a model for the distribution of baseline EQ5D0 was added to the
treatment received and outcome models. Bayesian posterior distributions of
the mean costs, QALYs and INB were then summarised by their median
value and 95% credible intervals. Table 2 shows that the CACE estimates
under MAR are broadly similar to those from the CCA, but in this example
the MI and Bayesian approaches provided estimates with wider CI. In gen-
eral, MI can result in more precise estimates than CCA, when the imputation
model does include auxiliary variables. The general conclusion of the study
is that surgery is relatively cost-effective in those patients with GORD who
are compliers. The results are robust to a range of approaches for handling
the non-compliance and missing data.
7 Further topics
We now consider further methodological topics relevant to health economic
studies faced with non-compliance and missing data. First, we discuss sensi-
2For simplicity we enforced a monotone pattern of missingness by excluding the three
individuals with missing EQ5D0 but observed costs, i.e. R0i = 0 but R1i = 1.
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Table 2: The REFLUX study: cost-effectiveness results according to esti-
mand, estimator and approach taken to missing data
 
 
Estimand Estimator Missing data 
assumption 
Missing data 
method 
Estimate of INB* (95% CI) 
surgery vs medical management 
ITT SUR CDM CCA 7,763 (-1,059 to 16,585) 
PP† SUR CDM CCA   4,620 (-4,927 to  14,167) 
     
CACE 3sls CDM CCA 10,275 (1,828 to 18,724) 
CACE BFL CDM CCA 10,353 (1,789 to 19,165) 
     
CACE 3sls MAR MI 13,587 (1,002 to 26,173) 
CACE 3sls MAR IPW 11,316 (5,244 to 17,388) 
CACE BFL MAR Bayesian 13,340 (1,406 to 26,315) 
*At a NICE recommended threshold of £30,000 per QALY gained 
† PP on CCA is based on   153  participants 
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tivity analyses for departures from the IV assumptions (section 7.1), and the
MAR assumption (section 7.2). We also consider approaches for addressing
non-compliance and missing data for non-continuous outcomes (section 7.3),
and clustered data (section 7.3.4) before offering conclusions and key topics
for further research (section 8).
7.1 Sensitivity analyses to departures from the IV as-
sumptions to adjust for non-compliance
The preceding sections detailed how an instrumental variable for the endo-
geneous exposure of interest can be used to provide consistent estimates of
the CACE as long as particular assumptions are met. However, it is helpful
to consider whether conclusions are robust to departures from these assump-
tions, in particular in those settings where these underlying assumptions
might be less plausible. For example, sensitivity to the exclusion restriction
assumption, can be explored by extending the Bayesian model described.
The analyst can specify priors on the non-zero direct effect of the IV on the
outcome (Conley et al., 2012; Hirano et al, 2000). Here it must be recognised
that as the models are only weakly identified, the results may be highly sen-
sitive to the parametric choices for the likelihood and the prior distributions.
Within the frequentist IV framework, sensitivity analyses can build on 3sls
to consider potential violations of the exclusion restriction and monotonicity
assumptions. See Baiocchi et al (2014) for a tutorial. Another important as-
sumption is that the IV strongly predicts treatment receipt, and this might
well be satisfied in most clinical trials (Zhang et al, 2014). In health eco-
nomics studies that use RCTs with encouragement designs, or Mendelian
randomisation observational studies where the IV is a gene, the IV may well
be weak, and this can lead to biased estimates. Here, Bayesian IV methods
have been shown to perform better than 2sls methods (Burgess and Thomp-
son, 2012).
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7.2 Sensitivity analyses to departures from MAR as-
sumptions
There has been much progress in the general econometrics and biostatistics
literature on developing methods for handling data that are assumed MNAR
(see for example Heckman (1976); Rubin (1987); Carpenter and Kenward
(2013)), but there are few examples in the applied health economics litera-
ture (Noble et al, 2012; Faria et al, 2014; Leurent et al, 2017; Jones et al,
2006) For settings when data are assumed to be MNAR, the two main groups
of methods proposed are: selection models and pattern mixture models. Se-
lection models postulate a mechanism by which the data are observed or
‘selected’, according to the true, underlying values of the outcome variable
(Heckman, 1979). By contrast pattern-mixture models specify alternative
distributions for the data according to whether or not they are observed
(Little and Rubin, 2002; Carpenter and Kenward, 2013).
Heckman selection models have been used in settings with missing sur-
vey responses particularly in HIV studies (see for example Clark and Houle
(2014)). Heckman’s original proposal was a two-step estimator, with a bi-
nary choice model to estimate the probability of observing the outcome in
the first stage, with the second stage then using the estimates in a linear
regression to model the outcomes (Heckman, 1976). Recent extensions allow
for other forms of outcomes, such as binary measures, by using GLMs for the
outcome equation (Marra and Radice, 2013), and recognise the importance of
appropriate model specification and distributional assumptions (Vella, 1998;
Das et al, 2003; Marchenko et al, 2012; McGovern et al, 2015). The Heck-
man selection model requires the selection model to include covariates not
in the outcome model, to avoid collinearity issues. This relies on an impor-
tant untestable assumption which tends to remain hidden: these variables
must meet the criteria for the exclusion restriction, that is, they must predict
missingness, and also be conditionally independent of the outcome (Puhani,
2000).
Pattern mixture models (PMM) have been advocated under MNAR as
they make more accessible, transparent assumptions about the missing data
mechanism (Molenberghs et al., 2014; Carpenter and Kenward, 2013). The
essence of the pattern-mixture model approach under MNAR is that it recog-
nises that the conditional distribution of partially observed variables, given
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the fully observed variables, may differ between units that do, and do not,
have fully observed data (Carpenter and Kenward, 2013). Hence, a PMM ap-
proach allows the statistics of interest to be calculated across the units with
observed data (pattern 1), and then for those with missing data (pattern
2). For the units with missing data, offsets terms are added to the statistics
of interest calculated from the observed data (pattern 2). The offset terms,
also known as sensitivity parameters, can differ according to the treatment
groups defined according to treatment assigned, or if there is non compli-
ance according to the treatment received. MI is a convenient way to perform
PMM sensitivity analyses. The offset method can be easily implemented for
variables which have been imputed under linear regression models. The soft-
ware package SAS has implemented PMM for other models within the MI
procedure MI.
As Leurent et al (2017) highlight in the context of health technology
assessment, few applied studies have used PMM. One potential difficulty is
that studies may have little rationale for choosing values for the sensitivity
parameters (Leurent et al, 2018). The general methodological literature has
advocated expert opinion to estimate the sensitivity parameters, which can
then be used as informative priors within a fully Bayesian approach (White
et al, 2007). Progress has been made by Mason et al (2017) who developed
a tool for eliciting expert opinion about missing outcomes for patients with
missing versus observed data, and then used these values in a fully Bayesian
analysis. In a subsequent paper Mason et al (2017) extend this approach to
propose a framework for sensitivity analyses in CEA for when data are liable
to be MNAR.
7.3 Other type of outcomes
The methods described have direct application to health economics studies
with continuous endpoints such as costs and health outcomes such as QALYs.
We now briefly describe extensions to settings with other forms of outcomes,
namely binary (e.g. admission to hospital) or time to event (duration or
survival) endpoints.
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7.3.1 Binary outcomes
Often, researchers are interested in estimating the causal treatment effect on
a binary outcome. The standard 2sls estimator requires that both stages to
be linear. This is often a good estimator for the risk difference, but may
result in estimates that do not respect the bounds of the probabilities, which
must lie between 0 and 1. Several alternative two-stage estimators have
been proposed. When odd ratios are of interest, two IV methods based on
plug-in estimators have been proposed (Terza et al, 2008). The first-stage
of these approaches is the same, a linear model of the endogenous regressor
D on the instrument Z (and the covariates X if using any in the logistic
model for the outcome). Where they differ is in the outcome model, the
second stage. The first strategy, so-called ‘standard’ IV estimator or two-
stage predictor substitution (2SPS) regression estimates the causal log odds
ratio with the coefficient for the fitted Dˆ. However, this will be biased for the
conditional odds ratio of interest, with the bias increasing with the strength
of the association between D and Y given Z. (Vansteelandt et al., 2011).
The second strategy, has been called ‘adjusted two-stage estimate’ or two-
stage residual inclusion (2SRI). The second-stage equation, i.e. the outcome
model, fits a logistic regression of Y on D and the residual from the first-
stage regression (as well as other exogeneous baseline covariates X, if using
any). However, the non-collapsibility of logistic regression means that 2SRI
only provides asymptotically unbiased estimates of the CACE if there is no
unmeasured confounding, i.e. when the model includes all the covariates that
predict non-compliance and the outcomes (Cai et al., 2012). This is because
when there is unobserved confounding, the estimate obtained by 2SRI is con-
ditional on this unobserved confounding, and since it is unobserved, cannot
be compared in any useful way with the population odds ratio of interest. If
we had measured those confounder, we could marginalise over their distri-
bution to obtain the population (marginal) odds ratio (Burgess, 2013). See
Clarke and Windmeijer (2012) for a comprehensive review of IV methods for
binary outcomes.
Chib and Hamilton (2002) developed simultaneous probit models, involv-
ing latent normal variables for both the endogenous discrete regressor and the
discrete dependent variable from the Bayesian perspective, while Stratmann
(1992) developed the full maximum likelihood version.
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The MI approaches previously described for handling missing data under
MAR and MNAR can all be applied to binary outcomes, for example by using
a logistic imputation model within FCS MI (Little and Rubin, 2002; Carpen-
ter and Kenward, 2013). The IPW strategies proceed for binary outcomes in
the same way as for continuous outcomes.
7.3.2 Time to event data
The effect of treatment on time to event outcomes, is often of interest for
example in oncology trials, or in evaluations of behavioural interventions,
where time to stop particular behaviour (e.g. time to smoking cessation) are
often reported.
A common IV method for estimating the causal effect of treatment receipt
on survival outcomes is the so-called rank preserving structural failure time
models (RPSFT) (Robins and Tsiatis, 1991), later extended to account for
censoring by White et al (1999) and applied to health technology assessment
by Latimer et al (2013, 2014). These models are called rank preserving,
because it is assumed that if subject i has the event before subject j when
both received the treatment, then subject i would also have a shorter failure
time if neither received the treatment i.e. Ti(a) < Tj(a), for a ∈ {0, 1}.
This is, randomisation is assumed to be an IV, and therefore to meet the
exclusion restriction such that the counterfactual survival times are assumed
independent of the randomised arm.
The target estimand is the average treatment effect amongst those who
follow the same treatment regime, i.e the average treatment effect on the
treated (ATT), as opposed to a CACE. In the simplest case, where treatment
is a one-off, all-or-nothing (e.g. surgery), let λT (1)(t) be the hazard of the
subjects who received the treatment.
We can use the g-estimation (Robins et al., 2000) procedure to obtain
the treatment-free hazard function λT (0)(t) to obtain λT (1)(t) = λT (0)(t)e
−β.
We refer to β as the causal rate ratio, as treatment multiplies the treatment-
free hazard by a e−β. As this is an IV method, it assumes that Z is a
valid instrument, however, instead of monotonicity, it requires that treatment
effect, expressed as β, is the same for both randomised arms, often referred
to as no effect modification by Z, which may be plausible in RCTs that
are double-blinded. This is a very strong assumption if, for example, the
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group randomised to the control regimen, receive the treatment later in the
disease pathway (e.g. post progression), compared to the group randomised
to treatment. This method has also been adapted for time-updated treatment
exposures.
7.3.3 Missing data in time to event analyses
For survival analysis, the outcome consists of a variable T representing time
to the event of interest and an event indicator Y . If Yi = 1, then that
individual had the event of interest at time Ti, but if Yi = 0, then Ti records
the censoring time, the last time at which a subject was seen, and still had
not experienced the event. This is a special form of missing data, as we know
that for individual i, the survival time exceeds Ti.
The censoring mechanism can be categorised as censored completely at
random (CCAR), where censoring is completely independent of the survival
mechanism; censoring at random (CAR), where the censoring is independent
of the survival time, conditional on the covariates that appear in the substan-
tive model, for example treatment. If even after conditioning on covariates,
censoring is dependent on the survival time, we say the censoring is not at
random (CNAR). CCAR and CAR are usually referred to as ignorable or
non-informative censoring.
Under non-informative censoring, we distinguish between two situations.
The first one is when the outcome is fully observed, but we have missing
values in the covariates that appear in the substantive model. The second is
when the survival time has missing values.
In some settings covariates X included in a Cox proportional hazards
model have missing values, White and Royston (2009) showed that when
imputing either a normally distributed or binary covariate X, we should use
a linear (or logistic) regression imputation model, with Y and the baseline
cumulative hazard function as covariates. To implement this, we have to es-
timate the baseline cumulative hazard function. White and Royston (2009)
suggested that when covariate effects are small, baseline cumulative hazard
can be approximated by the Nelson-Aalen (marginal) cumulative hazard esti-
mator, which ignores covariates and thus can be estimated using all subjects.
Otherwise, the baseline cumulative hazard function can be estimated within
the FCS algorithm by fitting the Cox proportional hazards model to the
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current imputed dataset, and once we have this, we can proceed to impute
X.
If the survival times are missing, according to CAR, that is condition-
ally on the covariates used in our analysis model, then the results will be
valid. MI can be helpful in situations where although the data are CAR,
we are interested in estimating either marginal survival distributions, or our
analysis model of interest includes fewer variables than required for the CAR
assumption to be plausible. A parametric imputation model, for example the
Weibull, log-logistic or lognormal is then used to impute the missing survival
times, see Carpenter and Kenward (2013).
7.3.4 Clustered data
Clustered data may arise when the health economics study uses data from
a multicentre RCT a cluster randomised trial, or indeed an observational
study where observations are drawn from high level units such as hospitals
or schools. In these settings but also those with panel or longitudinal data, it
is important to recognise the resultant dependencies within the data. Meth-
ods have been developed for handling clustering in health economics studies
including the use of multilevel (random effects) models (Grieve et al, 2010;
Gomes et al., 2012), but these have not generally been used in settings with
non-compliance. More generally there are methods to obtain CACE that ac-
commodate clustering. These range from simply using robust SE estimation
in an IV analysis (Baiocchi et al, 2014), to using multilevel mixture models
within the principal stratification framework (Frangakis and Rubin, 2002; Jo
et al , 2008). For extensions of principal stratification approaches to han-
dle non-compliance at individual and cluster-level, see Schochet and Chiang
(2011).
Regarding missing data, the FCS approach is not well-suited to proper
multilevel MI and so, when using MI, a joint modelling algorithm is used
(Schafer, 1997). The R package jomo can be used to multiply impute binary
as well as continuous variables. DiazOrdaz et al (2014, 2016) illustrate mul-
tilevel MI for bivariate outcomes such as costs and QALYs, to obtain valid
inferences for cost-effectiveness metrics, and demonstrate the consequences
of ignoring clustering in the imputation models.
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8 Discussion
This chapter illustrates and critiques methods for handling non-compliance
and missing data in health economics studies. Relevant methods have been
developed for handling non-compliance in RCTs with bivariate (DiazOrdaz
et al, 2017), or time to event endpoints (Latimer et al, 2013). Methods for ad-
dressing missing data under MAR have been exemplified in health economics
(Briggs et al, 2003), including settings with clustered data (DiazOrdaz et al,
2014).
Future studies are required that adapt the methods presented to the range
of settings typically seen in applied health economics studies, in particular to
settings with binary and time to event (duration) outcomes, and within longi-
tudinal or panel datasets where data are missing at intermittent time points.
To improve the way that non-compliance and missing data are handled, re-
searchers are required to define the estimand of interest, transparently state
the underlying assumptions, and undertake sensitivity analyses to departures
from the missing data, and identification assumptions.
Future health economics studies will have increased access to large-scale
linked observational data, which will include measures of non-adherence.
In such observational settings, there will be new possible sources of exoge-
nous variation such as genetic variants, resource constraints, or measures of
physician or patient preference that offer possible instrumental variables for
treatment receipt (von Hinke et al, 2016; Brookhart and Schneeweiss, 2007).
Future studies will be required to carefully justify the requisite identifica-
tion assumptions, but also develop sensitivity analyses to violation of these
assumptions. Here, the health economics context is likely to provoke require-
ments for additional methodological development. For example, sensitivity
analyses for the exclusion restriction (Jo, 2002a,b; Conley et al., 2012; Hi-
rano et al, 2000), may require refinement for settings where the exclusion
restriction is satisfied for one endpoint (e.g. QALYs) but not for another
(e.g. costs). Similarly, sensitivity analyses to the monotonicity assumption
have been developed in the wider methodological literature (Baiocchi et al,
2014; Small et al, 2017), but they warrant careful consideration in the health
economics context.
Further methodological research is required to allow for the more complex
forms of non-adherence that may be seen in applied health economic studies.
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Compliance may not always be all-or-nothing, or time invariant. For ex-
ample, there may be interest in the causal effect of the dose received. Here,
available methods may be highly dependent on parametric assumptions, such
as the relationship between the level of compliance and the outcome; alter-
natively a further instrument is required in addition to randomisation (Dunn
and Bentall, 2007; Emsley et al, 2010).
A promising avenue of future research for providing less model-dependent
IV estimates is to consider doubly robust estimators, such as targeted min-
imum loss estimation (TMLE) (van der Laan and Gruber, 2012), paired
with ensemble machine-learning approaches, for example the so-called Super
Learner (van der Laan et al., 2007). TMLE approaches for IV models have
recently been proposed (To´th and van der Laan, 2016). In the health eco-
nomics settings, TMLE has successfully been used for estimating the effects
of continuous treatments (Kreif et al, 2015).
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